Filing Flows › Caris Life Sciences (CAI) › How it makes money
How Caris Life Sciences (CAI) makes money
Caris Life Sciences (CAI) made $275M of revenue in the third quarter 2026 (Q3 2026), +27% from a year earlier. Molecular Profiling Services brought in $263M (95%); Pharma Research and Development Services brought in $12.7M (5%). Of every dollar of revenue, 7¢ was left as operating profit, 6¢ was left as net earnings.
Drawing the Sankey…
Revenue by segment, Q3 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Molecular Profiling Services | $263M | 95.4% | +4% | +27% |
| Pharma Research and Development Services | $12.7M | 4.6% | +10% | +37% |
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $275M | 100.0% |
| Operating profit | $19.3M | 7.0% |
| Income tax | $1.6M | 0.6% |
| Net earnings | $15.2M | 5.5% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $275M | +27% |
| Q2 2026 | $264M | +45% |
| Q1 2026 | $216M | +79% |
| Q4 2025 | $293M | +125% |
| Q3 2025 | $217M | +113% |
| Q2 2025 | $181M | +81% |
From Caris Life Sciences' 10-Q filed Nov 4, 2026 (on EDGAR).
Questions
How does Caris Life Sciences make money?
Caris Life Sciences (CAI) made $275M of revenue in the third quarter 2026 (Q3 2026), +27% from a year earlier. Molecular Profiling Services brought in $263M (95%); Pharma Research and Development Services brought in $12.7M (5%). Of every dollar of revenue, 7¢ was left as operating profit, 6¢ was left as net earnings.
What is Caris Life Sciences' biggest business?
Molecular Profiling Services: $263M in the third quarter 2026, 95% of revenue, +27% from a year earlier.
What is Caris Life Sciences' profit margin?
Net earnings were $15.2M, 5.5% of revenue, in the third quarter 2026; the operating margin was 7.0%.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.